A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis

التفاصيل البيبلوغرافية
العنوان: A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis
المؤلفون: Pedro Puech-Leão, Nelson Wolosker, Paulo Kauffman, José Ribas Milanez de Campos
المصدر: Journal of Vascular Surgery. 55(6):1696-1700
بيانات النشر: Elsevier BV, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Time Factors, Adolescent, medicine.drug_class, medicine.medical_treatment, Placebo-controlled study, Sweating, Muscarinic Antagonists, Placebo, Drug Administration Schedule, law.invention, Young Adult, Randomized controlled trial, law, Surveys and Questionnaires, medicine, Anticholinergic, Humans, Hyperhidrosis, Prospective Studies, Prospective cohort study, Oxybutynin, Chi-Square Distribution, business.industry, Compensatory hyperhidrosis, Middle Aged, Surgery, Treatment Outcome, Sympathectomy, Patient Satisfaction, Anesthesia, Quality of Life, Mandelic Acids, Female, medicine.symptom, business, Cardiology and Cardiovascular Medicine, Brazil, medicine.drug
الوصف: Introduction Video-assisted thoracic sympathectomy provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of oxybutynin, an anticholinergic medication that competitively antagonizes the muscarinic acetylcholine receptor, can be used to treat palmar hyperhidrosis with fewer side effects. Objective This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily) compared with placebo for treating palmar hyperhidrosis. Methods This was prospective, randomized, and controlled study. From December 2010 to February 2011, 50 consecutive patients with palmar hyperhidrosis were treated with oxybutynin or placebo. Data were collected from 50 patients, but 5 (10.0%) were lost to follow-up. During the first week, patients received 2.5 mg of oxybutynin once daily in the evening. From days 8 to 21, they received 2.5 mg twice daily, and from day 22 to the end of week 6, they received 5 mg twice daily. All patients underwent two evaluations, before and after (6 weeks) the oxybutynin treatment, using a clinical questionnaire and a clinical protocol for quality of life. Results Palmar and axillary hyperhidrosis improved in >70% of the patients, and 47.8% of those presented great improvement. Plantar hyperhidrosis improved in >90% of the patients. Most patients (65.2%) showed improvements in their quality of life. The side effects were minor, with dry mouth being the most frequent (47.8%). Conclusions Treatment of palmar and axillary hyperhidrosis with oxybutynin is a good initial alternative for treatment given that it presents good results and improves quality of life.
تدمد: 0741-5214
DOI: 10.1016/j.jvs.2011.12.039
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2457a3595f2fab439fd9bc887e691fTest
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....ed2457a3595f2fab439fd9bc887e691f
قاعدة البيانات: OpenAIRE
الوصف
تدمد:07415214
DOI:10.1016/j.jvs.2011.12.039